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Abstract 
The vast majority of patients with brain metastases from breast cancer have extracranial metastases, e.g., in the liver, 
lungs or bones, with serious impact on prognosis. Limited research has been performed on patients with brain-only 
disease. We analyzed patterns of treatment, brain control and survival in uni- and multivariate analyses. All 25 patients 
with brain-only disease were treated with radiotherapy (whole-brain radiotherapy (WBRT) with or without stereotac-
tic radiotherapy/radiosurgery (SRS) or surgical resection) and most patients with systemic treatment later during the 
disease trajectory. Only a minority of patients remained free from brain progression at 1 year after their initial therapy, 
regardless of initial treatment approach (median brain progression-free survival 6.2 months). However, overall survival 
was significantly better after initial surgical resection/SRS as compared to upfront WBRT (median 24.1 and 5.2 months, 
respectively). For all patients combined, median survival was 11.7 months (2-year survival rate 28 %). Several prognos-
tic factors for shorter survival were identified in multivariate regression analysis: lower KPS, triple-negative tumor, coor-
dination deficit, older age, lack of upfront surgical resection or SRS, and lack of endocrine or HER2-directed therapy 
after brain metastases treatment. Although durable brain control and long-term survival beyond 5 years could be 
achieved in a subset of patients (largely after successful salvage), progression of brain metastases during the first year 
after diagnosis was common. Prognosis was influenced by patient-, disease- and treatment-related factors.
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Background
Patients with newly diagnosed breast cancer often pre-
sent with clinically localized stage I or II disease and have 
low rates of disease recurrence, especially in the brain. 
Arvold et al. (2012) reported a study of more than 1400 
patients treated with breast-conserving therapy. Among 
patients who first developed extracranial metastases 
34  % eventually developed brain metastases, whereas 
among women who did not develop extracranial metas-
tases, <1 % developed brain metastases. Therefore, man-
agement of patients with brain-only metastases is less 
well studied, compared to the common scenario of both 
extra- and intracranial metastases (Lin et al. 2013).
Breast cancer subtype has been shown to correlate with 
risk of brain metastases. For example, Aversa et al. (2014) 
reported that patients with luminal tumors had the low-
est risk. Ahn et  al. (2013) found that time interval to 
diagnosis of brain metastases was shortest in the triple-
negative group. In one of the largest studies with pooled 
data from 24 member institutions of the Japan Clinical 
Oncology Group, 1256 patients with brain metastases 
were included (Niikura et  al. 2014). The median overall 
survival was 8.7  months. Patients with asymptomatic 
brain disease or HER2-positive/estrogen receptor-pos-
itive tumors had increased survival. In line with these 
results, Aversa et  al. (2014) reported that median sur-
vival after diagnosis of brain metastases was shortest in 
patients with triple-negative tumors. Having isolated 
brain metastases predicted significantly reduced risk of 
death [hazard ratio (HR) 0.37, p < 0.004] in their study.
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Since most studies included patients with and without 
extracranial metastases, and the results were dominated 
by the larger group of patients with extracranial metas-
tases, we decided to perform a retrospective study in 
patients with brain-only metastases. Given that this situ-
ation is uncommon, we pooled data from two different 
institutions.
Methods
All patients were females and treated for parenchymal 
brain metastases (not leptomeningeal disease) between 
2003 and 2012, either in Freiburg or Bodø, and identi-
fied from the institutional electronic databases of the 
Departments of Radiation Oncology (ARIA, Varian 
Medical Systems, Inc., Palo Alto, CA, USA). Initially we 
screened 992 patients with brain metastases from dif-
ferent primary cancers. We included 21 breast cancer 
patients without extracranial metastases and 4 patients 
whose extracranial metastases were in complete remis-
sion after successful therapy. Regarding these 4 patients, 
brain metastases developed 6–13 months after complete 
remission of extracranial metastases. Only one patient 
relapsed in a previously known extracranial site during 
follow-up.
Overall, 17  % of patients with brain metastases from 
breast cancer had brain-only disease. First breast can-
cer diagnosis dated back to as long as 1986 in one of the 
patients. Staging consisted of computed tomography 
(CT; thorax, abdomen, pelvis) and isotope bone scan. If 
necessary to resolve uncertain findings, magnetic reso-
nance imaging (MRI) and/or ultrasound were utilized. 
Screening for brain metastases in asymptomatic patients 
was not performed. Diagnosis was made by brain MRI 
and follow-up included further MRI every 3  months. 
Information about cognitive deficits and neurological 
symptoms was obtained from the physicians’ records. 
Prospective neurocognitive tests were not performed. 
Treatment consisted of whole-brain radiotherapy 
(WBRT), surgery, stereotactic radiotherapy/radiosurgery 
(SRS) or combinations thereof. Systemic therapy was at 
the discretion of the medical oncologists. At the time of 
analysis, 4 patients were alive (follow-up 29–70 months, 
median 48.5). Date of death was known in all other 
patients. Our definition of brain progression included the 
following events: new brain metastases or leptomenin-
geal enhancement, local relapse after surgical resection 
or after RT had resulted in complete remission, progres-
sion of previously treated lesions that never displayed 
complete remission (defined as an increase ≥25  % in at 
least one lesion, bidimensional measurement).
All analyses were performed with SPSS 22 (IBM, New 
York, USA). The Kaplan–Meier method was used to gen-
erate actuarial survival curves. These were compared 
with the log-rank test. Multivariate analysis of prognos-
tic factors was performed with the Cox proportional 
hazards model (forward stepwise data selection method; 
inclusion if univariate p value <0.15; univariate analysis 
performed for all baseline parameters reported in the 
Results section). Age and Karnofsky performance status 
(KPS) were entered as continuous variables. A p value 
≤0.05 was considered statistically significant. As a ret-
rospective quality of care analysis, no approval from the 
Regional Committee for Medical and Health Research 
Ethics (REK Nord) was necessary. This research project 
was carried out according to our institutions’ guidelines 
and with permission to access the patients’ data.
Results
Three patients (12 %) presented with brain metastases at 
first cancer diagnosis. These patients had untreated pri-
mary tumors. The median interval between first diagno-
sis and brain metastases was 29  months (range 0–292). 
Only five patients (20  %) had not received systemic 
therapy before diagnosis of brain metastases, includ-
ing the three patients with synchronous presentation. 
Eighteen patients (72  %) were previously exposed to 
chemotherapy, 8 to endocrine therapy (32  %), and five 
to trastuzumab (20  %), typically in the adjuvant setting. 
The patient characteristics are shown in Table  1. Initial 
treatment was surgical resection in 10 patients (40  %), 
SRS in one patient (4 %) and WBRT in 14 patients (56 %). 
Including salvage therapy, all but one patient received 
WBRT during the disease trajectory. The most common 
regimen was 10 fractions of 3 Gy (48 %), followed by 14 
fractions of 2.5  Gy (24  %). Salvage treatment included 
surgical resection (20  %), SRS (12  %), and fractionated 
stereotactic RT (20  %). After initial treatment for brain 
metastases 9 patients received chemotherapy (36 %), five 
endocrine treatment alone (20  %), and 3 trastuzumab 
(12  %). Overall, 10 patients remained without systemic 
therapy (40  %). If chemotherapy aimed at treatment of 
central nervous system relapse, the preferred options 
were capecitabine (n = 3) or temozolomide (n = 2).
Brain‑progression‑free survival (brain‑PFS)
This endpoint was based on date of brain-progression 
detected on imaging studies (n  =  11 events; only first 
progression was considered, not subsequent events 
in the same patient) or date of death if no progression 
was recorded (n =  10). Patients alive without progres-
sion were censored at last follow-up (n  =  4). Median 
Brain-PFS was 6.2 months and one-year Brain-PFS 22 %. 
Table  2 shows disease characteristics associated with 
Brain-PFS. Four factors significantly predicted for better 
outcome in multivariate analysis: higher KPS, cerebellar 
metastases, lack of cognitive and coordination deficits.
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Time to brain progression
This endpoint was evaluated because not all patients 
had regular imaging follow-up. Events were regis-
tered as follows: brain-progression detected on imag-
ing studies (n =  11; same criteria as outlined earlier), 
alive without progression (n = 4, censored at last imag-
ing follow-up), not imaged after treatment for brain 
metastases (n  =  5, censored at day 2 of treatment), 
imaging during initial follow-up only (n =  5, censored 
at last imaging follow-up). Median time to brain pro-
gression was 10.8  months and one-year freedom from 
progression 36 %. Four factors were associated with this 
endpoint (univariate): cerebellar metastases (p = 0.05), 
lack of cognitive and coordination deficits (p = 0.04 and 
0.03, respectively), and systemic therapy after treatment 
of brain metastases (p  =  0.06). However, multivariate 
analysis was unsuccessful because only 11 events were 
registered. All four patients who developed more than 
one progression in the brain eventually died from their 
brain metastases.
Overall survival
Median survival was 11.7  months, 1-year survival rate 
48  %, and 2-year survival rate 28  % (Fig.  1). In the Cox 
model with baseline patient- and disease-related factors, 
three of these predicted for significantly shorter survival: 
lower KPS, p = 0.007, triple-negative tumor, p = 0.05, and 
coordination deficit, p = 0.005. If treatment-related vari-
ables also were included in the model, three additional 
factors emerged: older age, p = 0.04, lack of upfront sur-
gical resection or SRS, p = 0.01, and lack of endocrine or 
HER2-directed therapy after brain metastases treatment, 
p =  0.01. Lack of endocrine or HER2-directed therapy 
after brain metastases treatment relates to the whole 
population irrespective of receptor status. Figure 2 shows 
the Kaplan–Meier curves for upfront WBRT vs. surgical 
resection/SRS. Median survival was 5.2 and 24.1 months, 
respectively. Figure  3 shows an example of the clinical 
course after successful radiotherapy.
Discussion
The aim of the present retrospective analysis was to eval-
uate management approaches and outcomes in patients 
with breast cancer who developed isolated spread to the 
brain. In our database from two different institutions 
only 17 % of patients with brain metastases from breast 
cancer had brain-only disease. In contrast to a prospec-
tive trial, staging was not standardized. Rather routine 
clinical practice guided the use of different imaging 
modalities. Possibly, prospective imaging protocols might 
Table 1 Patient characteristics, n =  25 (no male patients 
included)
KPS Karnofsky performance status, ER estrogen receptor, PR progesterone 
receptor
a Only one lesion was located in the brain stem
Median age, range (years) 58, 37–82
Median KPS, range 80, 50–100
KPS 80–100 vs. 70 vs. <70 (%) 80, 16, 4
Single brain metastasis (%) 24
More than 3 brain metastases (%) 60
Infratentorial metastases only/supratentorial metastases  
only/botha (%)
20, 40, 40
Controlled primary tumor (%) 88
Triple-negative tumor (%) 32
HER2 positive and ER/PR negative (%) 32




Coordination deficit (%) 12
Visual disturbance (%) 12
Seizures (%) 16
Motor deficit (%) 16
Speech disturbance (%) 36
Cognitive deficit (%) 24
Asymptomatic (%) 8
Table 2 Univariate and multivariate analysis of predictive factors for brain-progression-free survival (PFS)
^Karnofsky performance status (KPS) and number of brain metastases were entered as continuous variables
a Different stratifications were tested, all with comparable results






1–3 vs. >3 brain metastasesa 10.8 vs. 4.6 0.13 Not significant
Cerebellar vs. not 10.8 vs. 5.2 0.009 0.01
Cognitive deficit vs. none 3.1 vs. 10.8 0.02 0.02
Coordination deficit vs. none 4.6 vs. 6.9 0.06 0.01
KPS <80 vs. 80–100 2.1 vs. 8.9 0.13 0.009
Any systemic therapy vs. none (after local therapy for brain  
metastases)
9.8 vs. 4.6 0.02 Not significant
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have detected small extracranial metastases in some of 
the patients included in our study. The low frequency of 
brain-only disease was unexpected and limited the statis-
tical power of our analyses. In a multi-institutional study 
with 400 patients 35 % were free from extracranial metas-
tases (Sperduto et al. 2012). However, detailed analyses of 
this subgroup were not performed.
It has long been recognized that presence of extracra-
nial metastases is an important prognostic factor in the 
general population of patients with brain metastases (all 
primary tumors combined). For example, in the large 
study based on the Radiation Therapy Oncology Group 
(RTOG) database, median survival was significantly dif-
ferent, 4.8 vs. 7.1  months (Gaspar et  al. 1997). Possibly, 
the impact is slightly less pronounced in patients with 
primary breast cancer, because the difference observed 
in the multi-institutional study mentioned above was 
beyond the limit of statistical significance (median 12.9 
vs. 15.5  months) (Sperduto et  al. 2012). The absolute 
difference was comparable (2.3 and 2.6  months, respec-
tively). Regardless of statistical significance, the presence 
of extracranial disease is clinically relevant, because of 
its potential implications on organ function and choice 
of systemic therapy (Altundag et  al. 2007; Bartsch et  al. 
2006, 2007).
In our study, three patients (12 %) presented with brain 
metastases at first cancer diagnosis. The median inter-
val between first diagnosis and brain metastases was 
29 months (range 0–292). We also included four patients 
whose extracranial metastases were in complete remis-
sion after successful therapy. Their outcomes were fully 
comparable to those observed in patients without pre-
ceding other metastases. For example, one patient was 
alive after 29  months of follow-up, whereas three had 
died after 9, 18 and 43  months, respectively. Treatment 
was individualized and consisted of WBRT, surgery, SRS 
or combinations thereof. Systemic therapy was frequently 
prescribed, e.g., continuation of trastuzumab in patients 
who developed brain-only metastases during adjuvant 
treatment or while in complete remission after eradica-
tion of extracranial metastases. A weakness of our study 
is the fact that course of extracranial disease after diagno-
sis of brain metastases was not known in most patients. 
However, 10 patients (40 %) remained without systemic 
therapy, suggesting that development of extracranial 
metastases is not inevitable. Due to the lack of complete 
information on long-term extracranial disease status 
and the fact that many patients received terminal care 
at places other than the authors’ institutions, causes of 
death could not be analyzed.
Berghoff et al. (2012) performed a retrospective study 
covering the time period 1990–2011 that will be dis-
cussed in greater detail. Out of 60 patients with brain-
only recurrence, 37 % developed extracranial metastases 
during follow-up (median 7  months). The remaining 38 
patients formed the final study cohort. Breast cancer 
subtype was not associated with brain-only metastatic 
Fig. 1 Kaplan–Meier estimate of overall survival in 25 patients with 
brain-only metastases from breast cancer (n = 4 censored observa-
tions)
Fig. 2 Kaplan–Meier estimates of overall survival in patients with 
brain-only metastases from breast cancer treated with upfront whole-
brain radiotherapy vs. surgical resection or radiosurgery (n = 14 and 
11, respectively). Median 5.2 vs. 24.1 months, p = 0.04 (log-rank test)
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behavior. Median survival was 11  months, as compared 
to 11.7  months in our study. These figures are within 
the lower range of the 95  % confidence interval of the 
multi-institutional series (10.1–19.8  months) (Sperduto 
et  al. 2012). Berghoff et  al. (2012) identified two sig-
nificant prognostic factors, better KPS and single brain 
metastasis. Our results were somewhat different (KPS, 
triple-negative tumor, coordination deficit, age, surgi-
cal resection or SRS, and endocrine or HER2-directed 
therapy after brain metastases treatment), possibly as 
a result of the limited number of patients in both stud-
ies. With regard to our results it is important to realize 
that patients with triple-negative tumors are not eligible 
for endocrine or HER2-directed therapy. Niwinska et al. 
(2011) reported that patients with solitary brain metas-
tasis (single, brain-only; n = 29) survived for a median of 
20 months.
A large number of studies have investigated prognos-
tic factors for survival in patients with brain metastases 
from breast cancer and several collaborative groups have 
developed prognostic scores (Sperduto et al. 2012; Nieder 
et  al. 2009). A recent study by Subbiah et  al. (2015) 
was based on the breast graded prognostic assessment 
(breast-GPA), comprising age, tumor subtype, and KPS. 
Data were retrospectively gathered from a prospec-
tively maintained institutional database (1996–2013, 
n = 1552). The authors suggested a modified breast-GPA, 
which also includes number of brain metastases (>3 vs. 
≤3). In our study, age, tumor subtype and KPS were sta-
tistically significant too. Number of metastases was not 
significant, but the treatment-related parameter surgical 
resection or SRS is related to the presence of more than 3 
brain metastases.
The previously discussed study by Berghoff et al. (2012) 
did not analyze brain control. Our data suggest that dura-
ble brain control is difficult to achieve. Median Brain-
PFS was 6.2 months and one-year Brain-PFS 22 %. Even 
after excluding death without documented brain-relapse 
as one of the events that influence the Kaplan–Meier 
curves, one-year freedom from progression was limited 
to 36  %. It is known from previous studies that upfront 
surgery/SRS without WBRT carries a considerable risk 
of distant brain progression, i.e. new lesions outside of 
the initially treated region(s) (Nieder et al. 2014). At the 
same time, upfront WBRT employs palliative radiation 
doses, which are not sufficient to permanently eradicate 
Fig. 3 Magnetic resonance images before stereotactic fractionated radiotherapy in a 61-year old patient with solitary metastasis in the brain stem, 
HER2 positive disease, excellent performance status. The lesion received 7 fractions of 5 Gy prescribed to the 80 % isodose line. Two years later, 
radiation-induced changes developed, which resolved after treatment with steroids and pentoxifylline. The patient is alive without relapse
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all visible metastases, in particular those with large vol-
ume (Nieder et al. 1998; Mahmoud-Ahmed et al. 2002). 
The dominant pattern of progression is growth of known 
lesions (Nieder et  al. 1995). In principle, combina-
tion treatment (high doses to macroscopic tumor plus 
reduced doses to the other parts of the brain) might be 
beneficial (Rodrigues et  al. 2013; Oehlke et  al. 2015). 
However, no randomized trials have been performed that 
restricted inclusion to patients with brain-only disease. 
In mixed patient populations, no survival improvement 
was evident. Drugs that might reduce the risk of brain 
failure are not part of present clinical treatment algo-
rithms. However, ongoing research efforts might even-
tually lead to more efficacious approaches (Kodack et al. 
2015). With existing regimens, temporary responses can 
be obtained, which also might improve clinical symptoms 
in the context of palliation (Bachelot et al. 2013; Suther-
land et al. 2010).
Conclusions
It is presently unknown why selected patients with breast 
cancer develop brain-only metastatic disease, while 
most relapse in extracranial sites. Our data confirm pre-
vious studies that suggested a potential for long-term 
survival, also in patients who achieved complete remis-
sion of extracranial metastases after systemic treatment. 
Especially with upfront surgical resection/SRS median 
survival was 24.1  months. However, salvage treatment 
is often required. It is therefore important to repeatedly 
assess optimal local therapy and indication for systemic 
treatment in multidisciplinary expert panels.
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